ArticleBMC pulmonary medicine2026
Predictors of survival and transplantation outcomes in Japanese patients with interstitial lung disease referred for lung transplantation: a retrospective single-center study.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung transplantation is a vital therapeutic option for patients with advanced interstitial lung diseases (ILDs) unresponsive to conventional treatments. In Japan, challenges for this treatment include a long waiting period (average, 2.5 year) and the absence of a comprehensive scoring system. Identifying predictors of survival and transplantation outcomes is critical for improving patient management and optimizing donor lung allocation. This study aimed to examine the clinical characteristics and outcomes of Japanese ILD patients referred for lung transplantation, focusing on factors associated with death and transplantation as competing risks.
methodsThis retrospective, single-center study included patients with ILD referred to a lung transplant clinic between April 2009 and March 2020. Patients were followed until death or study-end censoring. Diagnoses were established through multidisciplinary discussion, incorporating surgical lung biopsy, bronchoscopic examinations, and high-resolution computed tomography. Statistical analyses (R 4.4.2) treated death and transplantation as competing events. Univariate and multivariate Fine–Gray models were used to evaluate factors influencing the subdistribution hazard ratio (sHR) for death. Cumulative incidence functions for death and transplantation were compared using the Gray test.
resultsAmong 65 patients (mean age, 52.0 ± 7.9 years; 66% male), 15% underwent transplantation and 42% died before transplantation. The median time to transplantation was 585 days. Univariate Fine–Gray analysis showed that log-transformed C-reactive protein (CRP_ln) was significantly associated with increased mortality risk, whereas partial pressure of oxygen in arterial blood (PaO₂) and percent predicted diffusing capacity of the lung for carbon monoxide (%DLCO) were significantly associated with low mortality risk. Multivariate analysis confirmed that CRP_ln and PaO2 independently influenced mortality. Significant differences in the cumulative incidence of death were observed for PaO₂ (cutoff, 80 Torr), %DLCO (cutoff, 40%), and home oxygen therapy. For transplantation probability, Krebs von den Lungen-6 (KL-6; cutoff, 1,400 U/mL) showed a significant difference (p = 0.03).
conclusionsIn Japanese ILD patients referred for lung transplantation, PaO₂, %DLCO, and CRP_ln were independent predictors of mortality. KL-6 was associated with transplantation probability. Continuous monitoring of these biomarkers could aid in the efficient allocation of donor lungs, given the scarcity of donors and prolonged waiting times in Japan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.